Chronic kidney disease medications
Pro Research Analysisby 
Searched over 200M research papers
Medication Safety and Drug Selection in Chronic Kidney Disease
Patients with chronic kidney disease (CKD) are at increased risk for medication-related harm due to altered drug metabolism and excretion. Many drugs can worsen kidney function or cause nephrotoxicity, so careful selection and dosing are essential. For example, bisphosphonates and hypnotics can accelerate CKD progression, while denosumab does not. Tenofovir disoproxil fumarate (TDF) is associated with kidney and bone toxicity, but newer alternatives like tenofovir alafenamide (TAF) and tenofovir amibufenamide (TMF) are safer for the kidneys. Some antiviral medications, such as nirmatrelvir/ritonavir and remdesivir, require dose adjustments or caution in severe CKD, while molnupiravir does not need adjustment. Close monitoring and choosing safer alternatives can help reduce drug-induced harm in CKD patients .
Commonly Used Medications and Dose Adjustments in CKD
CKD patients often require multiple medications to manage complications and comorbidities. Common drug classes include adrenal glucocorticoids, immunosuppressants, diuretics, renin-angiotensin-aldosterone system (RAAS) inhibitors, anticoagulants, and antibiotics. Because most drugs are excreted by the kidneys, dose adjustments based on kidney function are often necessary to avoid drug accumulation and side effects. Guidelines for the general population may not always apply to CKD patients, so individualized therapy is important .
Polypharmacy and Medication Burden in CKD
Polypharmacy—defined as the use of five or more medications daily—is highly prevalent among CKD patients, with rates approaching 80%. The number of medications increases with CKD severity, age, and comorbidities such as diabetes and cardiovascular disease. Commonly used drugs include β-blockers, angiotensin-converting enzyme inhibitors (ACEi), and statins. Polypharmacy increases the risk of drug interactions and adverse effects, highlighting the need for careful medication review and management 35.
Novel and Established Pharmacological Strategies for CKD
Traditional management of CKD focuses on controlling blood pressure, glucose, and albuminuria, often using ACE inhibitors or angiotensin receptor blockers (ARBs). Statins are used to manage dyslipidemia. Newer therapies include sodium-glucose cotransporter 2 (SGLT2) inhibitors, which slow CKD progression and offer cardiovascular benefits, and non-steroidal mineralocorticoid receptor antagonists, which reduce inflammation and fibrosis with fewer side effects like hyperkalemia. Other promising drugs include finerenone, canakinumab, and pentoxifylline. Research is ongoing into therapies targeting vitamin D, uric acid, erythropoietin, phosphate, endothelin receptors, and inflammatory pathways 4789+1 MORE.
Medication Stewardship and Risk Reduction in CKD
Drug stewardship is crucial for CKD patients to maximize safety and effectiveness. This involves medication reconciliation, selection, dose adjustment, monitoring, and deprescribing when appropriate. Special considerations are needed for elderly patients, who are at higher risk for inappropriate prescriptions and adverse effects. Regular reassessment of medications, especially those with renal risks or those considered potentially inappropriate for the elderly, is recommended. Patient education, digital health tools, and interdisciplinary collaboration can further improve medication safety and access 56.
Conclusion
Managing medications in chronic kidney disease requires careful selection, dose adjustment, and ongoing review to minimize harm and optimize outcomes. Polypharmacy is common and increases the risk of adverse effects, especially in elderly patients. Newer drug classes and stewardship strategies offer hope for better kidney and cardiovascular protection, but individualized care and vigilance remain essential for this vulnerable population 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic